MORI-BUILDING
18.2.2021 06:02:05 CET | Business Wire | Press release
Mori Building Co., Ltd., Japan’s leading urban landscape developer, announced today that it will partner with Aman, the operator of diverse world-class luxury hotels and resorts, in the Toranomon-Azabudai Urban Redevelopment Project, a massive urban renewal undertaking that will revitalize a large area of central Tokyo when completed in 2023. The two main outcomes of the partnership will be the branded residence Aman Residences, Tokyo and luxury hotel Janu Tokyo , Aman’s sister brand, marking the debut of the Janu brand in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217006076/en/
Shingo Tsuji, President and CEO of Mori Building, said: “Tokyo must add to its magnetic power if it is to succeed in its competition with the world’s greatest cities. Mori Building is joining hands with Aman, which operates diverse world-class resorts, to provide a world-leading residential environment and hotel unlike anything ever seen in Tokyo, where people will achieve harmony with nature as well as connect with and inspire others through creativity. By realizing this new form of ‘urban wellness,’ Mori Building will enhance Tokyo's magnetic power.”
Vladislav Doronin, Chairman and CEO of Aman and Janu, said: “Launching our first urban Aman Residences in Japan is a milestone moment in the history of Aman and speaks to our brand’s close relationship and symbiosis with this country and its incredibly special culture. Working with leading developers Mori Building, and being part of the Toranomon-Azabudai project, will enable us to bring to life Aman’s fifth development within Japan, this time offering a permanent sanctuary for owners as well as exclusive access to the Aman lifestyle. Furthermore, it will provide the setting for Janu Tokyo. In this hub of culture and art, we want to connect guests to the heart of this vibrant community and offer a chance for creative expression.”
Aman Residences, Tokyo — incomparable urban residential experiences
Aman Residences, Tokyo will be located on floors 54–64 of the 330-meter A District Tower, will offer 91 hotel-branded residences with exclusive services, including a residents-only Aman Spa (some 1,400 m²). Aman’s signature hospitality—both warm and unassuming—will enable residents to enjoy extraordinarily peaceful lifestyles while overlooking the vibrant Tokyo metropolis. The Tower’s sophisticated architectural design is the masterful work of Pelli Clarke Pelli Architects (USA) and interior design has been crafted by Yabu Pushelberg (Canada).
Janu Tokyo — Aman’s sister brand debuts in Japan
Aman’s luxury hotel brand Janu will make its Japan debut with Janu Tokyo on floors 1–13 in the B-2 District Tower. The hotel is designed by Denniston (Malaysia) under the leadership of Jean-Michel Gathy. In addition to approx. 120 luxury rooms, all offering excellent views of a central square filled with lush greenery, Janu Tokyo will boast Japan’s largest spa (some 3,500 m²) with spa treatment and a fitness center, six restaurants, and a cafe and bars for leisure and business gatherings. Janu Tokyo will welcome guests from around the world.
About Aman
Aman was founded in 1988 with the vision of building a collection of intimate retreats with the unassuming, warm hospitality of a gracious private home. The first, Amanpuri (place of peace) in Phuket, Thailand, introduced the concept and, since then, Aman has grown to encompass 33 exquisitely serene hotels and resorts in 20 destinations across the world, with a further seven under construction. The next Aman to open will be Aman New York. In 2020, a new hotel brand, Janu - meaning ‘soul’ in Sanskrit was unveiled. Janu offers a unique take on hospitality where genuine human interaction, playful expression and social wellness are at the core of the experience. Janu aims to bring balance to the head and heart and rekindle the soul. Janu launches with three forthcoming hotels which are already under construction: Montenegro (2022), Al Ula in Saudi Arabia (2022) and Tokyo (2023), as well as a robust pipeline of future hotels.
About Mori Building
Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residence. The concept is applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. Please visit www.mori.co.jp/en
Related Links
Press release “Mori Building Unveils Massive Urban Regeneration Project In Central Tokyo” published on August 22, 2019:
https://www.mori.co.jp/en/img/article/190822.pdf
Toranomon-Azabudai Project Fact Book:
https://www.mori.co.jp/en/projects/toranomon_azabudai/img/fact_book.pdf
Toranomon-Azabudai Project Image Movie:
https://www.youtube.com/watch?v=5akVE7tWOto&feature=emb_logo
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217006076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom